Wells Fargo believes that investors are failing to recognize the potential of YM's lead drug as a treatment for indications other than myelofibrosis. However, the firm believes that YM is undervalued based on the drug's potential in myelofibrosis alone, and it maintains an Outperform rating on the stock.
Asian shares and the euro eased on Tuesday, with a relief rally from last week's heavy selling faltering quickly …
There are no comments yet